Guido Zaman is the Managing Director and founder of Oncolines B.V., a Symeres company specializing in precision medicine services in oncology and cancer immunotherapy. Oncolines supports clinical and preclinical biopharma companies, as well as academic institutions worldwide, in differentiating their drugs and drug candidates through advanced cancer cell line profiling, mechanism-of-action studies, bioinformatics and biochemical assays.

Previously, Guido was also co-founder of Netherlands Translational Research Center (NTRC), a biotech company established in Oss in 2011 by former employees of Organon/MSD. He holds a Ph.D. in Science from Radboud University Nijmegen and conducted post-doctoral research for five years at the Netherlands Cancer Institute in Amsterdam, focusing on drug transporters in the laboratory of Prof. Piet Borst

Before becoming a biotech entrepreneur, Guido held various project and line management roles at Organon/MSD, where he contributed to drug discovery programs targeting protein kinases, G protein-coupled receptors and nuclear hormone receptors in the Immunology and Women’s Health therapeutic areas.

Guido is a named inventor on seven granted patents and has co-authored over 90 publications in peer-reviewed scientific journals.